Skip to main content

Integration of Chikungunya research

Objective

Since 2005 Chikungunya fever has affected millions of people producing a high fever and a debilitating arthralgia which can persist for months and progress to chronic arthritis. Chikungunya virus has been associated with periodic outbreaks of human disease and is spread by mosquitoes. The current epidemic rose to prominence in 2005/6 following infection of >250,000 people on La Réunion. The virus rapidly spread to other islands in the Indian Ocean, India and SE Asia. Chikungunya cases in returning travellers have been reported. In summer 2007 a traveller from India to Italy initiated a locally transmitted outbreak which included one death from encephalitis. The mosquitoes transmitting this infection are spreading and increasing in Europe and could spread as far north as the British Isles. There are diagnostics tests, these require standardisation. The pathogenic mechanisms leading to myalgia, arthralgia, rare encephalitis and chronic arthritis are unknown precluding rational therapeutic intervention. There are no antivirals. There is no licensed vaccine. This project will integrate the expertise of EU laboratories with a long and strong track record of research on alphaviruses with EU laboratories that started work on CHIKV following the outbreak in La Réunion and laboratories from SE Asia working on this virus. The project will generate new molecular and cellular tools for research and applied studies, including high-throughput screening and vaccines; standardise, quality assure and distribute key diagnostic tests and develop new ones; determine virus genetic changes across time, geographical regions and species; discover interactions between virus and human cells to inform rational design of therapeutics; study immune responses in the chronic disease in humans, including whether virus persists in joints, the cell types involved and the relationship to immune responses; characterise rodent and non-human primate models of acute and chronic infection to further study the pathogenesis and provide models for antiviral and vaccine screens; screen libraries of characterized pharmaceutical and bioactive compounds for antiviral activity and develop a vaccine which at the end of this project is ready to enter clinical trials.

Call for proposal

FP7-HEALTH-2010-single-stage
See other projects for this call

Coordinator

THE PIRBRIGHT INSTITUTE LBG
Address
Ash Road Pirbright
GU24 0NF Woking
United Kingdom

See on map

Activity type
Research Organisations
Administrative Contact
Sara Hurst (Ms.)
EU contribution
€ 364 309,85

Participants (14)

KAROLINSKA INSTITUTET
Sweden
EU contribution
€ 370 782
Address
Nobels Vag 5
17177 Stockholm

See on map

Activity type
Higher or Secondary Education Establishments
Administrative Contact
Peter Liljestroem (Prof.)
TARTU ULIKOOL
Estonia
EU contribution
€ 221 774
Address
Ulikooli 18
51005 Tartu

See on map

Activity type
Higher or Secondary Education Establishments
Administrative Contact
Andres Merits (Prof.)
HELSINGIN YLIOPISTO
Finland
EU contribution
€ 283 176
Address
Yliopistonkatu 3
00014 Helsingin Yliopisto

See on map

Activity type
Higher or Secondary Education Establishments
Administrative Contact
Tero Ahola (Dr.)
INSTITUT PASTEUR
France
EU contribution
€ 107 432
Address
Rue Du Docteur Roux 25-28
75724 Paris Cedex 15

See on map

Activity type
Research Organisations
Administrative Contact
Nadia Khelef (Dr.)
UNIVERSITE DE LA REUNION
France
EU contribution
€ 324 729
Address
Avenue Rene Cassin 15
97715 Saint Denis De La Reunion Cedex 9

See on map

Activity type
Higher or Secondary Education Establishments
Administrative Contact
Philippe Gasque (Prof.)
COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES
France
EU contribution
€ 452 757
Address
Rue Leblanc 25
75015 Paris 15

See on map

Activity type
Research Organisations
Administrative Contact
Etienne Garderet (Mr.)
UNIVERSITATSKLINIKUM BONN
Germany
EU contribution
€ 262 440
Address
Venusberg-campus 1
53127 Bonn

See on map

Activity type
Higher or Secondary Education Establishments
Administrative Contact
Beate Becker (Ms.)
STEINBEIS INNOVATION GGMBH
Germany
EU contribution
€ 245 000
Address
Adornostrasse 8
70599 Stuttgart

See on map

Activity type
Research Organisations
Administrative Contact
Uwe Haug (Mr.)
BIOMEDICAL SCIENCES INSTITUTES Limited by Guarantee
Singapore
EU contribution
€ 10 000
Address
Biopolis Way 20
138668 Singapore

See on map

Activity type
Research Organisations
Administrative Contact
Lisa F.P. Ng (Dr.)
UNIVERSITY OF MALAYA
Malaysia
EU contribution
€ 64 545
Address
Lembah Pantai
50603 Kuala Lumpur

See on map

Activity type
Higher or Secondary Education Establishments
Administrative Contact
Sazaly Abu Bakar (Prof.)
THE UNIVERSITY OF EDINBURGH

Participation ended

United Kingdom
EU contribution
€ 255 493,75
Address
Old College, South Bridge
EH8 9YL Edinburgh

See on map

Activity type
Higher or Secondary Education Establishments
Administrative Contact
Angela Noble (Ms.)
AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS
Spain
EU contribution
€ 37 500
Address
Calle Serrano 117
28006 Madrid

See on map

Activity type
Research Organisations
Administrative Contact
María ángeles López Vázquez (Ms.)
UNIVERSITY OF GLASGOW
United Kingdom
Address
University Avenue
G12 8QQ Glasgow

See on map

Activity type
Higher or Secondary Education Establishments
Administrative Contact
Joe Galloway (Mr.)
GRIFFITH UNIVERSITY
Australia
Address
Kessels Road Nathan
4111 Brisbane

See on map

Activity type
Higher or Secondary Education Establishments
Administrative Contact
Kath Murrie-Jones (Ms.)